ES2722773T3 - Polipéptidos de fHbp meningocócicos modificados - Google Patents
Polipéptidos de fHbp meningocócicos modificados Download PDFInfo
- Publication number
- ES2722773T3 ES2722773T3 ES15738352T ES15738352T ES2722773T3 ES 2722773 T3 ES2722773 T3 ES 2722773T3 ES 15738352 T ES15738352 T ES 15738352T ES 15738352 T ES15738352 T ES 15738352T ES 2722773 T3 ES2722773 T3 ES 2722773T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- polypeptide
- meningococcal fhbp
- fhbp polypeptides
- modified meningococcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 101710186862 Factor H binding protein Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un polipéptido que comprende una secuencia de aminoácidos que tiene al menos un 80 % de identidad de secuencia con la SEQ ID NO: 5, en el que (a) la secuencia de aminoácidos difiere de la SEQ ID NO: 5 en los restos 123 y 240 con respecto a la SEQ ID NO:5; (b) el polipéptido puede, después de la administración a un ser humano, generar anticuerpos que pueden reconocer un polipéptido que consiste en la SEQ ID NO: 4; (c) el polipéptido tiene una mayor estabilidad que un polipéptido que consiste en la SEQ ID NO: 4; y (d) el polipéptido tiene una menor afinidad para fH humano que un polipéptido que consiste en la SEQ ID NO: 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14177564 | 2014-07-17 | ||
| PCT/EP2015/066228 WO2016008960A1 (en) | 2014-07-17 | 2015-07-16 | Modified meningococcal fhbp polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2722773T3 true ES2722773T3 (es) | 2019-08-16 |
Family
ID=51178812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15738352T Active ES2722773T3 (es) | 2014-07-17 | 2015-07-16 | Polipéptidos de fHbp meningocócicos modificados |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11066450B2 (es) |
| EP (1) | EP3169357B1 (es) |
| JP (1) | JP2017522320A (es) |
| KR (1) | KR20170023191A (es) |
| CN (1) | CN106795208A (es) |
| AR (1) | AR102324A1 (es) |
| AU (1) | AU2015289192A1 (es) |
| BE (1) | BE1022641B1 (es) |
| BR (1) | BR112017000521A2 (es) |
| CA (1) | CA2954745A1 (es) |
| EA (1) | EA201692552A1 (es) |
| ES (1) | ES2722773T3 (es) |
| IL (1) | IL249822A0 (es) |
| MX (1) | MX2017000776A (es) |
| SG (1) | SG11201610945PA (es) |
| TR (1) | TR201901062T4 (es) |
| WO (1) | WO2016008960A1 (es) |
| ZA (1) | ZA201700170B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802933T4 (tr) | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| SG10201907875TA (en) * | 2014-02-28 | 2019-09-27 | Glaxosmithkline Biologicals Sa | Modified meningococcal fhbp polypeptides |
| EA038940B1 (ru) | 2014-07-17 | 2021-11-12 | Глаксосмитклайн Байолоджикалс С.А. | Менингококковые вакцины |
| CA2954745A1 (en) | 2014-07-17 | 2016-01-21 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| WO2016014719A1 (en) * | 2014-07-23 | 2016-01-28 | Children's Hospital & Research Center Oakland | Factor h binding protein variants and methods of use thereof |
| BR112019010625A2 (pt) * | 2016-11-25 | 2019-10-22 | Glaxosmithkline Biologicals Sa | conjugado imunogênico, processo para preparar o conjugado imunogênico, nomv-ligante intermediário, usos do mesmo e de nomv, composição imunogênica, e, vacina. |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| IT201900003947A1 (it) * | 2019-03-19 | 2020-09-19 | Mt Ortho S R L | Granulo in materiale metallico biocompatibile per vertebroplastica. |
| CN114929660A (zh) | 2019-12-19 | 2022-08-19 | 陶氏技术投资有限责任公司 | 用于制备异戊二烯和包含至少六个碳原子的单烯烃的方法 |
| AU2022223712A1 (en) | 2021-02-19 | 2023-10-05 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
| GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| TW202423477A (zh) | 2022-08-03 | 2024-06-16 | 美商賽諾菲巴斯德公司 | 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| CN102172398A (zh) | 2000-01-17 | 2011-09-07 | 诺华疫苗和诊断有限公司 | 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗 |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CA2779816A1 (en) * | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| BR112012022669A2 (pt) | 2010-03-10 | 2017-02-14 | Glaxosmithkline Biologicals Sa | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
| TR201802933T4 (tr) | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| GB201120634D0 (en) | 2011-11-30 | 2012-01-11 | Univ Sheffield | Adjuvant polypeptide |
| EP2861247B1 (en) | 2012-06-14 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Vaccines for serogroup x meningococcus |
| GB201215005D0 (en) | 2012-08-23 | 2012-10-10 | Isis Innovation | Stabilised meningitis vaccine |
| SG10201907875TA (en) | 2014-02-28 | 2019-09-27 | Glaxosmithkline Biologicals Sa | Modified meningococcal fhbp polypeptides |
| CA2954745A1 (en) | 2014-07-17 | 2016-01-21 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| EA038940B1 (ru) | 2014-07-17 | 2021-11-12 | Глаксосмитклайн Байолоджикалс С.А. | Менингококковые вакцины |
-
2015
- 2015-07-16 CA CA2954745A patent/CA2954745A1/en not_active Abandoned
- 2015-07-16 BR BR112017000521A patent/BR112017000521A2/pt not_active Application Discontinuation
- 2015-07-16 BE BE2015/5456A patent/BE1022641B1/fr not_active IP Right Cessation
- 2015-07-16 AU AU2015289192A patent/AU2015289192A1/en not_active Abandoned
- 2015-07-16 JP JP2017502626A patent/JP2017522320A/ja active Pending
- 2015-07-16 SG SG11201610945PA patent/SG11201610945PA/en unknown
- 2015-07-16 US US15/319,651 patent/US11066450B2/en active Active
- 2015-07-16 EP EP15738352.2A patent/EP3169357B1/en active Active
- 2015-07-16 CN CN201580038763.8A patent/CN106795208A/zh active Pending
- 2015-07-16 EA EA201692552A patent/EA201692552A1/ru unknown
- 2015-07-16 KR KR1020177004243A patent/KR20170023191A/ko not_active Withdrawn
- 2015-07-16 ES ES15738352T patent/ES2722773T3/es active Active
- 2015-07-16 WO PCT/EP2015/066228 patent/WO2016008960A1/en not_active Ceased
- 2015-07-16 TR TR2019/01062T patent/TR201901062T4/tr unknown
- 2015-07-16 MX MX2017000776A patent/MX2017000776A/es unknown
- 2015-07-16 AR ARP150102268A patent/AR102324A1/es unknown
-
2016
- 2016-12-28 IL IL249822A patent/IL249822A0/en unknown
-
2017
- 2017-01-09 ZA ZA2017/00170A patent/ZA201700170B/en unknown
-
2021
- 2021-06-14 US US17/346,362 patent/US11939357B2/en active Active
-
2024
- 2024-02-12 US US18/438,870 patent/US20240327470A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11066450B2 (en) | 2021-07-20 |
| EA201692552A1 (ru) | 2017-06-30 |
| BR112017000521A2 (pt) | 2017-11-21 |
| US20220002355A1 (en) | 2022-01-06 |
| EP3169357A1 (en) | 2017-05-24 |
| US11939357B2 (en) | 2024-03-26 |
| AR102324A1 (es) | 2017-02-22 |
| WO2016008960A1 (en) | 2016-01-21 |
| IL249822A0 (en) | 2017-03-30 |
| CN106795208A (zh) | 2017-05-31 |
| JP2017522320A (ja) | 2017-08-10 |
| AU2015289192A1 (en) | 2017-02-02 |
| CA2954745A1 (en) | 2016-01-21 |
| EP3169357B1 (en) | 2018-11-07 |
| US20170226161A1 (en) | 2017-08-10 |
| ZA201700170B (en) | 2019-06-26 |
| KR20170023191A (ko) | 2017-03-02 |
| BE1022641A1 (fr) | 2016-06-23 |
| MX2017000776A (es) | 2017-05-04 |
| TR201901062T4 (tr) | 2019-02-21 |
| BE1022641B1 (fr) | 2016-06-23 |
| SG11201610945PA (en) | 2017-01-27 |
| US20240327470A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| MX2019010461A (es) | Plataforma de identificacion de peptidos inmunogenicos personalizada. | |
| CY1123622T1 (el) | Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
| MX2017004559A (es) | Receptores de celulas t. | |
| TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
| MX2017010880A (es) | Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario. | |
| DOP2016000051A (es) | Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
| ES2671434T3 (es) | Antagonistas de Kv1.3 y métodos de uso | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| CO2017012675A2 (es) | Péptidos lipidados resistentes a proteasas | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| MX380859B (es) | Nuevos derivados de cath2. | |
| AR108688A1 (es) | Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso | |
| BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno |